Tumore al polmone, Fondo farmaci innovativi importante ma va migliorato

adnkronos

(Adnkronos) -  Nella lotta al tumore del polmone i farmaci innovativi fanno la differenza e il Fondo dedicato, che li rende disponibili, è fondamentale. Ci sono però delle scelte da fare perché tale opportunità sia anche più efficiente. Oltre a includere anche i farmaci con innovatività condizionata, è importante che dopo 6 anni non escano dal fondo, ma restino almeno per 10 anni Sono i temi al centro del Convegno nazionale ‘Inventing for lung. Il contributo dell’innovazione per il trattamento del tumore al polmone’, promosso da Msd Italia. Nel corso dell’evento sono state presentate anche 2 indagini: quelle di Bva Doxa su ‘il tumore al polmone, tra bisogni di conoscenza e fake news’ e il report Ihe (The Swedish Insitute for Health Economics) sull’accesso ai farmaci oncologici innovativi in Italia.

Transcript

00:00A collective strategy to fight lung cancer,

00:07among innovative drugs, the state fund that makes them available

00:11and the choices to make to make it even more efficient.

00:14This was discussed at the national convention promoted by MSD Italy

00:18on the contribution of innovation to the treatment of lung cancer.

00:22The right time to present two investigations such as that of BV Addoxa,

00:26the lung cancer between need for knowledge and fake news

00:29and the IHE report, the Swedish Institute for Health Economics,

00:33on access to innovative oncological drugs in Italy.

00:37We are the first biopharmaceutical company in the world for research intensity,

00:4242% of our revenue,

00:44which means more than 30 billion dollars invested in research and development last year,

00:50which also equate to our 105 million euros,

00:54which are very important because they equate to a total of 700 million euros

00:58invested in research and development by the entire pharmaceutical sector in Italy.

01:04It means, in terms of innovation, access to innovation immediately to patients

01:09and, above all, opportunities to be truly included in what is the great engine of research.

01:15A research that is the heart of therapies,

01:17just like our fund for the realization of these innovative drugs is at the epicenter of everything

01:23and also represents a model in Europe.

01:25For the record, our country has a reimbursability rate equal to 83%,

01:31higher than the European average.

01:32As they are better, also the access times to the same treatments,

01:35after EMA approval, 417 days compared to 559.

01:40Only that from us, in 2023, 35% of the funds remained unused,

01:45spending only 770 million on 1.2 billion.

01:49We still record 44,000 new cases a year.

01:54This tumor still has a close link with cigarette smoke.

01:58The introduction of drug-targeted molecular therapy

02:01and the introduction of immunotherapy have radically changed

02:06what our treatment algorithm is,

02:08which means that patients who receive these treatments

02:12have a discreet quality of life

02:16and have a much longer life expectancy

02:19than what we could achieve with only chemotherapy.

02:22But in such an important battle, we cannot stop.

02:25For this reason, Anna Maria Mancuso, President of Salute Donna ODV

02:29and coordinator of the group La Salute, Un Bene da Difendere, Un Diritto da Promuovere,

02:33has indicated the way to ensure a further step forward.

02:36The access times are quite long, I would say.

02:42Just think that they go through three levels,

02:46that is, EMA, AIFA and regions.

02:49This amendment provides for the extension of the possibility

02:53within AIFA to consider an innovative drug

02:57within 10 years, not 6,

02:59as a limit to what is now considered.

Category

Transcript

Recommended